Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis

NCT03573323 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03573323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03573323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
November 9, 2018
Completion date
January 8, 2020
Enrollment
1,027 (actual)
Sites
124

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis